Uracil compounds and their antitumor applications
A compound and representative technology, applied in the field of medicinal chemistry, can solve the problems of short plasma half-life, poor patient compliance, and poor tumor selectivity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0054] Example 1 , (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl n-hexyloxyformate
[0055]
[0056] Commercially available 5-fluorouracil (compound of formula II, 1.3 g, 0.01 mol) was dissolved in 15 mL of 37% formaldehyde solution, stirred at 50° C. for 3 hours, and the reaction was detected by TLC. The reaction solution was concentrated to dryness under reduced pressure to obtain compound III, which was used in the next reaction.
[0057] Dissolve 0.01 mol of compound III obtained above in 20 mL of dichloromethane, add triethylamine (2.02 g, 0.02 mol), then add hexyloxychloroformate (III', 1.97 g, 0.012 mol) in batches, and stir at room temperature for 2 hours , TLC monitored the end of the reaction. The reaction solution was washed successively with saturated brine and saturated sodium bicarbonate solution, the organic phase was concentrated, and the residue was subjected to silica gel column chromatography (eluent V 石油醚 :V 乙酸乙酯 =5: 1) Separation and puri...
Embodiment 2
[0060] Embodiment 2, (5-Fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl n-decyloxyformate
[0061] Referring to the method of Example 1, compound III was reacted with n-decyloxyformyl chloride to obtain the title compound as a white solid, which can be referred to as compound 2 in the present invention.
[0062] 1 H NMR (500MHz, CDCl 3 )δ8.59(s,1H),7.65(d,J=5.36Hz,1H),5.67(s,2H),4.20(t,J=6.88Hz,2H),1.33-1.25(m,16H), 0.87(t,J=6.89Hz,3H).
[0063] MS-ESI(m / z):345(M+H) + .
Embodiment 3
[0064] Embodiment 3, (5-Fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl n-tetradecyloxycarboxylate
[0065] Referring to the method of Example 1, compound III was reacted with n-tetradecyloxycarbonyl chloride to obtain the title compound as a white solid, which may be referred to as compound 3 in the present invention.
[0066] 1 H NMR (500MHz, CDCl 3 )δ8.63(s,1H),7.62(d,J=5.36Hz,1H),5.66(s,2H),4.19(t,J=6.86Hz,2H),1.34-1.25(m,24H), 0.87(t,J=6.99Hz,3H).
[0067] MS-ESI(m / z):401(M+H) + .
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


